Ferguson Wellman Capital Management Inc. Acquires 266 Shares of Danaher Co. (NYSE:DHR)

Ferguson Wellman Capital Management Inc. increased its holdings in shares of Danaher Co. (NYSE:DHR) by 17.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,785 shares of the conglomerate’s stock after acquiring an additional 266 shares during the period. Ferguson Wellman Capital Management Inc.’s holdings in Danaher were worth $446,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in DHR. ST Germain D J Co. Inc. increased its position in Danaher by 1.4% during the 1st quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after purchasing an additional 41 shares during the period. Godsey & Gibb Inc. boosted its holdings in shares of Danaher by 3.0% in the 1st quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock valued at $360,000 after buying an additional 42 shares in the last quarter. Nicholas Hoffman & Company LLC. boosted its holdings in shares of Danaher by 2.3% in the 4th quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after buying an additional 43 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in shares of Danaher by 1.3% in the 4th quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock valued at $803,000 after buying an additional 43 shares in the last quarter. Finally, Berger Financial Group Inc boosted its holdings in shares of Danaher by 1.7% in the 4th quarter. Berger Financial Group Inc now owns 2,517 shares of the conglomerate’s stock valued at $582,000 after buying an additional 43 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In related news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Rainer Blair sold 9,005 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the sale, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The disclosure for this sale can be found here. In the last quarter, insiders sold 47,712 shares of company stock valued at $13,173,269. 11.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on DHR. Citigroup raised their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. SVB Leerink lifted their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Robert W. Baird lifted their target price on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, Bank of America lifted their target price on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $276.88.

Danaher Stock Performance

Shares of NYSE:DHR traded down $0.58 during trading on Wednesday, hitting $268.13. 923,732 shares of the stock traded hands, compared to its average volume of 2,873,703. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The company has a market cap of $198.60 billion, a price-to-earnings ratio of 45.54, a P/E/G ratio of 4.62 and a beta of 0.83. The company has a fifty day moving average price of $257.53 and a two-hundred day moving average price of $252.98. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s quarterly revenue was down 2.9% on a year-over-year basis. During the same period in the previous year, the firm earned $2.05 EPS. As a group, equities analysts predict that Danaher Co. will post 7.59 EPS for the current year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.